US EditionTrump announces reforms to accelerate access to psychedelic drug treatments
The order directs federal agencies to speed reviews, fund research and open a pathway for veterans to access early treatments.
- On Saturday, President Donald Trump signed an executive order in the Oval Office to expedite research into psychedelic drugs, including ibogaine, for treating serious mental health conditions.
- Citing data that over 14 million Americans suffer from serious mental illness, HHS Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan urged the president to pursue these therapies.
- Officials committed $50 million to research while directing the Food and Drug Administration to accelerate review timelines via priority vouchers and extend 'Right to Try' provisions for eligible patients.
- Despite the order, ibogaine remains classified as Schedule I, meaning it is illegal outside clinical settings; experts warn of potential cardiovascular risks requiring rigorous clinical validation.
- Proponents believe these therapies could offer veterans life-changing relief where traditional medications have failed, potentially reducing the over 6,000 annual veteran suicides that exceed combat deaths since 9/11.
282 Articles
282 Articles
Trump Signs Psychedelic Research Order With Joe Rogan at White House
President Trump signed an executive order on April 18, 2026, aimed at expanding federal research into psychedelic drugs, including ibogaine. Officials said the move is intended to accelerate studies into new treatments for mental health conditions, particularly among veterans and patients who have not responded to existing therapies. The announcement took place at the White House with Joe Rogan in attendance, alongside Robert F. Kennedy Jr. and …
Predsednik SAD Donald Tramp potpisao je izvršnu uredbu kojom se ubrzava postupak odobravanja i isstraživanja psihodeličnih droga, uključujući ibogain, koji se pominje kao mogući treatment za posttraumatski stressni pormećaj (PTSP), prenosi Index.hr.
Sydney Morning Herald
Trump signs order to speed up access to psychedelic drug treatments
The US President’s latest executive order expedites the review of drugs such as ibogaine, which he said came to his attention partly through the efforts of podcaster Joe Rogan.
U.S. President Donald Trump signed an executive order this Saturday to boost research into psychedelics such as LSD, psilocybin and ibogain as new treatment options for people with severe mental health disorders. The directive sets out new guidelines for the Food and Drug Administration (FDA) to expand researchers’ access to these substances, now classified as illegal drugs in the U.S., in strictly controlled therapeutic settings.
President Trump Signs An Executive Order On Psychedelic Drugs With Special Guest Joe Rogan
I wasn’t expecting to see President Trump alongside podcaster Joe Rogan anytime soon. On Saturday, President Trump signed an executive order on the use of psychedelic drugs for medical research and clinical trials. Noticeably behind President Trump during the Executive Order signing ceremony was Joe Rogan. Take a look: WOW! Joe Rogan reveals President Trump IMMEDIATELY offered him FDA approval for a psychedelic treatment in a text chain Because…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
